These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 29709013

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM, Wattanachanya L, Apornpong T, Jantrapakde J, Avihingsanon A, Kerr SJ, Teeratakulpisarn N, Jadwattanakul T, Chaiwatanarat T, Buranasupkajorn P, Ramautarsing R, Phanuphak N, Sunthornyothin S, Ruxrungtham K, Phanuphak P, TNT 003.1 study team.
    PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
    Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, Kolta S, Costagliola D, Rozenberg S, ANRS Osteovir study group.
    AIDS; 2013 Sep 24; 27(15):2425-30. PubMed ID: 24029735
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.
    Negredo E, Bonjoch A, Puig J, Echeverría P, Estany C, Santos JR, Moltó J, Pérez-Álvarez N, Ornelas A, Clotet B.
    New Microbiol; 2015 Apr 24; 38(2):193-9. PubMed ID: 25938744
    [Abstract] [Full Text] [Related]

  • 8. The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Alvarez E, Campbell L, Tinago W, Garcia-Leon A, Walsh I, Brady JJ, Burling K, Noe S, Neuville MF, Jouret F, Jamshidian F, Graham H, Rhee M, Mallon PW, Post FA.
    Antivir Ther; 2022 Aug 24; 27(4):13596535221094898. PubMed ID: 36000318
    [Abstract] [Full Text] [Related]

  • 9. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J.
    AIDS; 2003 Sep 05; 17(13):1917-23. PubMed ID: 12960824
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-Term Impact of Calcium and Vitamin D Supplementation on Bone Density in HIV+ Patients with Documented Deficiencies.
    Faber J, Bech A, van Bentum P, Gisolf J, Hassing RJ, de Boer H.
    AIDS Res Hum Retroviruses; 2020 Jan 05; 36(1):58-64. PubMed ID: 31523978
    [Abstract] [Full Text] [Related]

  • 12. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term use of protease inhibitors is associated with bone mineral density loss.
    Kinai E, Nishijima T, Mizushima D, Watanabe K, Aoki T, Honda H, Yazaki H, Genka I, Tanuma J, Teruya K, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
    AIDS Res Hum Retroviruses; 2014 Jun 30; 30(6):553-9. PubMed ID: 24494779
    [Abstract] [Full Text] [Related]

  • 16. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
    Escota GV, Mondy K, Bush T, Conley L, Brooks JT, Önen N, Patel P, Kojic EM, Henry K, Hammer J, Wood KC, Lichtenstein KA, Overton ET.
    AIDS Res Hum Retroviruses; 2016 Jan 30; 32(1):59-67. PubMed ID: 26366785
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men.
    Paccou J, Viget N, Drumez E, Cortet B, Robineau O.
    Med Mal Infect; 2018 Oct 30; 48(7):442-448. PubMed ID: 29699830
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercié P, Morlat P, Thiébaut R, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    AIDS; 2008 Jan 30; 22(3):395-402. PubMed ID: 18195566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.